Mark Bierhoff
Gastroenterology · Philadelphia, PANPI 1568527372
Payments from drug & device makers
Across 437 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$739
- Gilead$717
- Takeda Pharmaceuticals U.S.A., Inc.$604
- Johnson & Johnson$574
- Merck$410
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$7009%
- Food & beverage$7,08991%
- Gifts$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 124 | $2,477 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 50 | $739 |
| Gilead | 53 | $717 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $604 |
| Johnson & Johnson | 31 | $574 |
| Merck | 26 | $410 |
| Ironwood Pharmaceuticals, Inc | 18 | $266 |
| Nestle Healthcare Nutrition Inc. | 10 | $216 |
| Redhill Biopharma Inc. | 14 | $206 |
| QOL Medical, LLC | 10 | $168 |
| Pfizer | 10 | $156 |
| Braintree Laboratories, Inc. | 8 | $142 |
| Intercept Pharmaceuticals, Inc. | 8 | $139 |
| E.r. Squibb & Sons, L.L.C. | 1 | $124 |
| Janssen Scientific Affairs, LLC | 1 | $120 |
| Bristol Myers Squibb | 7 | $115 |
| UCB, Inc. | 7 | $100 |
| Shionogi Inc | 5 | $73 |
| Concordia Pharmaceuticals Inc. | 4 | $56 |
| Steris Corporation | 1 | $50 |
| Pharmacosmos Therapeutics Inc. | 2 | $44 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Digestive Care, Inc. | 1 | $38 |
| Ardelyx, Inc. | 2 | $37 |
| Shire North American Group Inc | 2 | $34 |
| Ferring Pharmaceuticals Inc. | 2 | $30 |
| Dova Pharmaceuticals | 2 | $29 |
| Evoke Pharma, Inc. | 1 | $22 |
| Sandoz | 1 | $22 |
| Axonics, Inc. | 1 | $21 |
| W. L. Gore & Associates, Inc. | 1 | $19 |
| Mauna Kea Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,804 in reported general payments places this provider in the 70th percentile of 935 gastroenterology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 18 | $57,581 |
| LinzessLinaclotide | 38 | $24,787 |
| Mesalamine | 18 | $11,749 |
| Ursodiol | 11 | $738 |
| Omeprazole | 48 | $420 |
| Famotidine | 25 | $341 |
| Dicyclomine Hcl | 14 | $311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $739 | $57,58118 claims |
| AbbVieLinzess | $2,477 | $24,78738 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 935 gastroenterology providers in Pennsylvania.
Other gastroenterology in Philadelphia
- Kuchikala ReddyPhiladelphia$6.5M
- Dina Halegoua de MarzioPhiladelphia$1.5M
- Gary FalkPhiladelphia$1.4M
- Kristle LynchPhiladelphia$1.3M
- Gary WuPhiladelphia$931K
- Faten AberraPhiladelphia$909K
- Ben StangerPhiladelphia$815K
- David KaplanPhiladelphia$737K
- Stacey PrennerPhiladelphia$577K
- Mark OstermanPhiladelphia$410K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.